

---

# Pharmacy Benefits Management Dear Manufacturer Letter

Public Law 102-585 Section 603

(38 U.S.C. 8126)

The Veteran's Healthcare Act of 1992 ("the Act")



Pharmacy Benefits Management (PBM) Services  
1<sup>st</sup> Ave – 1 Blk N of Cermak Rd  
Bldg 37 Rm 139 (10P4P)  
Hines, IL 60141  
Annual Compliance

October 13, 2022

*Additional copies available at: <http://www.va.gov/oal/business/fss/publicLaw.asp>.*

TABLE OF CONTENTS

I.	Introduction .....	3
II.	Background .....	3
	a. Purpose .....	3
	b. Expectations .....	3
	c. System requirements .....	3
III.	Public Law Timetable (Overview).....	3
IV.	Detailed Timeline .....	4
V.	Excel Data Dictionary.....	5-6
VI.	General Guidance .....	7-8
VII.	Attachments .....	9-14
	A. Methodology Changes .....	9
	B. Workbook Verification Disputes.....	10-11
	C. Compliance reminders .....	12
	D. FCP Disputes .....	13
	E. Self-Disclosure .....	14
	F. Appeal to the Nominal Increase Board.....	15

**I. INTRODUCTION**

The Office of Pharmacy Benefits Management Services (PBM) is responsible for maintaining calculated federal ceiling prices (FCPs) for covered drugs through the Public Law annual reporting process. All companies of covered drugs are obligated to comply with the reporting requirements under Public Law 102-585, Section 603.

**II. BACKGROUND**

Public Law 102-585, also referred to as the Veterans Healthcare Act of 1992 (“the Act”), became law on November 4, 1992. Section 603 of the Act and the provisions of each company’s Master Agreement (MA) require companies to report annual non-Federal Average Manufacturer’s Price (non-FAMP) calculations for covered drugs. Information about the Act is available on the Office of Acquisition and Logistics—Federal Supply Schedule Service (FSS) website at: <http://www.va.gov/oal/business/fss/publicLaw.asp>.

**a. PURPOSE**

The purpose of this Dear Manufacturer Letter (DML) is to provide companies with guidance on complying with the 2022 annual non-FAMP reporting requirements (for 2023 FCPs) under Public Law 102-585, Section 603. *Please retain a copy of this DML as it contains guidance in Parts VI and VII of this letter on various Public Law issues that frequently occur.*

**b. EXPECTATIONS**

PBM will provide your company’s point of contact with an Excel workbook that is pre-populated with data. It is the company’s responsibility to verify the accuracy of the data in this workbook. Follow the guidance in this letter to report any disputes to the VA. If there are no disputes to the pre-populated data in the Excel workbook, you are advised to populate the workbook with data values as explained in this letter and return electronically to VA before the November 15, 2022, deadline. The excel data dictionary and Attachment C provide a list of compliance reminders to assist with your annual filing.

**c. SYSTEM REQUIREMENTS**

To comply with the annual reporting requirements, electronic mail (e-mail) and a computer loaded with Microsoft Excel (.xls) program is required.

**III. 2022 Year PUBLIC LAW TIMETABLE (OVERVIEW)**

NLT OCT 1	NAC Letter	Letter from National Acquisition Center (NAC) providing guidance on how Jan 1 FSS pricing updates will proceed
NLT OCT 17	CPI-U Published & workbooks distributed	PBM calculates the consumer price index-urban (CPI-U%) value and disseminates company's Excel workbook containing covered drugs subject to annual calculations
OCT 18	Workbook Verification	Company reviews VA's workbook for discrepancies, which may include omissions, FSS price disputes, 3Q disputes or any other discrepancies that may exist and notifies VA
Starting OCT 19	FCP Calculations	PBM will start/continue to process the annual reports; NOTE: pending disputes will be resolved prior to FCP calculations.
OCT 29	Deadline	Last day for companies to submit methodology change requests & related 3Q OLD restatements under (proposed) new methodology; This is also the last day companies may report any disputes identified in the company workbook (FSS Disputes, omissions and 3Q disputes <u>unrelated</u> to methodology change)
NOV 15	Deadline	Annual filing due.
NOV 21	Deadline	Last day to submit request for modification (RFM) to NAC for guaranteed Jan 1 upload price

#### IV.

#### DETAILED TIMELINE

##### No Later Than (NLT) October 15, 2022

Companies' designated non-FAMP representative will receive an e-mail from [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) on behalf of the Public Law Manager. This e-mail will contain attachments of a current copy of PBM's DML and an Excel workbook (.xls) of covered items subject to annual calculations. This Excel workbook (.xls), which is a locked version and contains select prepopulated cells, will be used by companies to complete the 2022 annual non-FAMP reporting requirements (for 2023 FCPs). Pages 5-6 of this DML provide the data dictionary of this Excel workbook.

##### By October 18, 2022

Workbook Verification: **Companies must review the Excel workbook upon receipt for any disputes and discrepancies.**

Companies are advised to notify the VA of any disputes in the Excel workbook via e-mail as outlined in this guidance letter. Please note not all covered drugs are eligible for annual non-FAMP calculations; the workbook will only contain covered items that are subject to the annual non-FAMP calculation reporting. Companies must report all covered drug items that had/should have had a Permanent FCP in place on September 30, 2022, for the purpose of determining FCPs for Calendar Year 2023.

**NOTE: the FSS price that is in effect on September 30, 2022, as reflected in this workbook, which is used for Public Law calculations, does not include the Industrial Funding Fee (IFF) or the Federal Excise Tax (FET) for vaccines. Disputes and discrepancies should follow the dispute process outlined in Attachment B.**

##### Starting October 19, 2022

The PBM Public Law Team will start to calculate the covered items' changes in non-FAMP, additional discounts (if any), and the 2022 FCP (if not already in process). Companies are encouraged to submit their annual reports early, as FCP calculations are completed on a first-in first-out basis. Once the calculations are completed, the Excel workbook (.xls) will be sent by e-mail to the companies' designated non-FAMP representative. **Companies have two business days to review the 2023 FCPs and provide concurrence.** Attachment D instructs how to submit FCP disputes by e-mail.

##### By October 29, 2022

- Deadline for companies to report and describe modifications in existing methodology used to calculate non-FAMP, and to request approval to restate 3Q 2021 (non-FAMP OLD) according to the new methodology (for purposes of an apples-to-apples additional discount calculation). This request must be submitted via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov), as instructed in Attachment A. The VA will review the requests and communicate a resolution to the company. At this point, and to reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company. To ensure accuracy in calculations, please provide a copy of the approved methodology communication when your company files the annual report. Companies that submit 3Q disputes due to methodology change requests after October 29 can expect increased delays in receiving their 2023 FCP calculations.
- Deadline for companies to report any Workbook Verification disputes via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov), as instructed in Attachment B. Disputes can include any combinations of: a covered drug's FSS price that was in effect or awarded on September 30, 2022; any dispute(s) of the calculated non-FAMP for the 3Q non-FAMP Old value (07/01/2021 through 09/30/2021); the listing of drug items subject to the annual calculations, such as omitted items; or other disputes as to the accuracy of the contents of the Excel workbook (.xls) that was received. The VA will validate the disputes and communicate a resolution to the company. To reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company.
- To ensure accuracy, please provide a copy of VA's approved resolution when your company files the annual report.

##### By November 15, 2022

- Companies must report the annual non-FAMP (10/01/2021 through 09/30/2022) and 3Q non-FAMP New (07/01/2022 through 09/30/2022) calculations to the VA via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) using the Excel workbook (.xls) provided by the PBM Public Law Manager. At this point in time, PBM will only re-issue corrected workbooks for extreme cases. **IMPORTANT:** Your Company must include a copy of VA's approved resolution for identified disputes when filing the annual report to the VA. It is possible that your company has submitted disputes by the requested deadline to the VA, but the disputes are pending VA resolution. To remain compliant with the November 15 filing deadline, the company must submit their annual filing along with a copy of the original dispute verification e-mail along with current resolution status, if any. Calculations will not begin until all disputes have been resolved. Attachment C provides a list of compliance reminders.

##### By November 21, 2022

Companies' authorized signatories must prepare and sign a new PPA addendum, listing each covered drug and its 2023 FCP. The VA National Acquisition Center (NAC) FSS Service will be issuing additional guidance no later than October 1, 2022, on how to submit a "Request For Modification" (RFM) via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) to update contract pricing. The properly prepared RFM must be received by **November 21, 2022**, to guarantee an effective date of January 1, 2023.

## V.

## EXCEL DATA DICTIONARY

Field Name	Definition	Edits Allowed
ID	Unique identifier assigned to item in Public Law database	No
YearID	Calendar year in which the Federal Ceiling Price applies	No
Prep_date	Date the report is prepared by company. Format = "mm/dd/yyyy" NOTE: Date entered restricted to 10/01/2022 and 01/15/2023	Yes
ndc_1	National Drug Code (NDC); ndc_1 = Labeler code (5 digits)	No
ndc_2	NDC; ndc_2 = Product code (4 digits)	No
ndc_3	NDC; ndc_3 = Package code (2 digits)	No
Unt_pkg	Number of units per package	No
Date_enter	Date the NDC was reported as first commercially available for sale	No
Dose_form	Dosage form of the NDC	No
Strength	NDC strength	No
FDA_name	NDC name reported by company as listed on FDA registration form	No
Trade_name	NDC brand name reported by company	No
Generic_name	NDC generic name	No
Pct_cpiu	Percent Increase in Consumer Price Index (CPI-U). Calculated by multiplying the difference between the two index numbers by 100 and that product divided by the older of the two CPI-U's. Calculation is rounded to two decimal places; rounding up if 3 <sup>rd</sup> decimal is >=5. <i>Examples: 2.1462 rounds to 2.15; 2.1449 rounds to 2.14</i>	No
fss	2022 Federal Supply Schedule (FSS) price; the permanent contract price in effect or awarded on September 30, 2022 for single price companies. For dual FSS pricing companies, the 2022 FSS price is September 30, 2022 awarded permanent contract price charged to other government agencies and authorized FSS users other than the Department of Veterans Affairs (VA), Department of Defense (DoD), US Coast Guard or Public Health Service (PHS). NOTE: The FSS price in this field DOES NOT include the Industrial Funding Fee (IFF) for companies that embed this fee or the Federal Excise Tax (FET) if applicable.	No
fssmax	2022 Maximum Price; calculated using FSS + Allowable CPI-U% increase.	No
nfamp	2022 Annual Non-Federal Average Manufacturer price (non-FAMP = "nfamp" in Excel Table for ease of reference) is the weighted average manufacturers' sales price for the NDC. <b>Calculation is rounded to two decimal places; rounding up if 3<sup>rd</sup> decimal is &gt;=5. For "false positive" non-FAMPs (negative sales divided by negative units), and no reportable sales, "0.00" should be entered. Activity resulting in negative values should be reported as such. Do not return spreadsheet with blank values.</b>	Yes
nfamp_old	Non-FAMP for 07/01/2021 thru 09/30/2021. See "nfamp" field above for calculation and reporting requirements.	No
nfamp_new	Non-FAMP for 07/01/2022 thru 09/30/2022. See "nfamp" field above for general calculation and reporting requirements.	Yes
nfamp_chg	Difference between "nfamp_new" and the "nfamp_old". This number can be negative. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.	No

Field Name	Definition	Edits Allowed
add_disc	Difference between “nfamp_chg” and the legislative allowable increase. The allowable increase is the product of the “nfamp_old” and “Percent_cpiu”. This number must be $\geq$ \$0.00. If “nfamp_chg” is negative, then \$0.00 will be populated. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.	No
calcmax	2022 Calculated Ceiling. Calculation based on 38 U.S.C.8126 (d)(2),(a)(2) and (c) is the product of the annual non-FAMP X 0.76, less “add_disc” (additional discount). Calculation is rounded to two decimal places; rounding up if 3 <sup>rd</sup> decimal is $\geq$ 5. <i>Examples: 2.1462 rounds to 2.15; 2.1449 rounds to 2.14</i> NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.	No
fcg	2023 Federal Ceiling Price (FCP). Lower of 38 U.S.C. 8126(d)(1) or 38 U.S.C. 8126 (d)(2), (a)(2) & (c). This field is determined by using the lower number of fssmax or calcmax. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.	No
disc_date	This field represents a covered item’s discontinuation date from the manufacturer’s FSS. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.	No
cnt_no	FSS contract number assigned by the National Acquisition Center (NAC); current as of 9/30/2022	No
company_of	Name of the company’s official authorizing and certifying that the data provided in this workbook is accurate	Yes
dispute_fss	Enter a “Y” to dispute the FSS price. Follow the directions outlined in Attachment C or E, as applicable. <b>If dispute_fss field = Y, then rev_fss field must be populated.</b>	Yes
dispute_nfamp_old	Enter a “Y” to dispute the 3Q old non-FAMP data if unrelated to methodology change. Please follow the directions in Attachments A, D or E, as applicable. <b>If dispute_nfamp_old = Y, then Rev_nfamp_old field must be populated.</b>	Yes
rev_fss	Revised FSS price; if company populates the dispute_fss field, then rev_fss should not be blank; <b>Calculation is rounded to two decimal places</b> ; rounding up if 3 <sup>rd</sup> decimal is $\geq$ 5.	Yes
Rev_nfamp_old	Revised 3Q old value, if company populates the dispute_nfamp_old field, then rev_nfamp_old should not be blank; <b>Calculation is rounded to two decimal places</b> ; rounding up if 3 <sup>rd</sup> decimal is $\geq$ 5.	Yes
non_taa	This field indicates covered item(s) which have been identified as items sourced from a non-U.S., non-designated country under the requirements of the Trade Agreements Act (TAA). They are considered covered drugs as defined by the Veteran’s Health Care Act of 1992, P.L. 102-585, Sect. 603, therefore, your company must continue to report non-FAMP to PBM for any covered drug and maintain a FCP for the drug annually with PBM.	No

## VI.

### .GENERAL GUIDANCE

Each covered drug's mandated FCP for 2023 (the fifth year of FSS multiyear contracts for statutory purposes) will be determined by adopting the lower of two calculation results. These two calculations are described in (1) 38 U.S.C. 8126 (d) (1) and (2) 38 U.S.C. 8126 (d) (2), (a) (2) & (c). The same percent change in Consumer Price Index-Urban (CPI-U) will be utilized in performing both calculations. This change in CPI-U is identified as the percent change from September 2021 to September 2022. Using data from the **U.S. Bureau of Labor Statistics, the derived percent change was calculated as 8.20%. This will be used as the CPI-U figure for the 2023 FCP calculations.**

The Federal Excise Tax (FET) on vaccines and the one-half of one percent (0.5%) IFF being incorporated into FSS contracts **will not** be included in calculations of non-FAMP or reporting of FCPs but will be included in the FSS/Big 4 (Department of Veterans Affairs, Department of Defense (DoD), Public Health Service/Indian Health Service, & U.S. Coast Guard) selling price. Please see additional instructions from your respective contracting officer(s).

The Section 8126 (d) (1) calculation will begin with the **permanent FSS contract price of a covered drug in effect on September 30, 2022.** FSS temporary price reduction pricing is not used as the FSS price in effect on September 30, 2022, for the purposes of the dual calculation. The dual calculation is performed for both the single and dual pricing options. For those manufacturers that elected dual FSS pricing, **the FSS contract price is the September 30, 2022, price charged to other government agencies** and other authorized Schedule users; **not** the price paid by the Big 4. The appropriate FSS price will then be increased by the above percent change in CPI-U to arrive at the 2023 FSS price cap (FSS Max). This cap applies to all "other users" FSS prices in 2023.

The Section 8126 (a) (2) & (c) calculation (Calc Max) will begin by multiplying the 2022 annual non-FAMP by 0.76 and then subtracting any additional discount. The additional discount is the difference between the "old" non-FAMP increased by CPI-U and the "new" non-FAMPs. **The lower of the Calc Max calculation and the 2022 FSS price cap (FSS Max) will become the 2023 FCP.** If there are "no sales" in a benchmark third quarter of a year that is used to derive the new non-FAMP or old non-FAMP, there can be no additional discount calculation for that particular item. In those cases, negative non-FAMPs should be reported, and no additional discount will be calculated; additional discount will be entered as zero (0.00). **If a covered drug had no reportable sales in the 2022 annual non-FAMP period, its calculated 2023 FCP will be the lower of: (A) the 2022 FCP increased by an amount equal to the 2022 FCP multiplied by the percent change to the CPI-U (as explained and provided above) OR (B) the FSS price in effect on September 30, 2022 increased by an amount equal to the September 30, 2022 FSS price multiplied by the percent change to the CPI-U.**

If they meet the other VA criteria, nominal prices excludable from non-FAMP's for 2022 calculations must be prices that are less than 10 percent of that particular item's non-FAMP during the third quarter of 2021 (07/01/2021 through 09/30/2021). Where sales to end-users are required for calculation of non-FAMP due to the absence of wholesale sales, you need not include purchases by PHS grantees or disproportionate share hospitals ("covered entities") if the prices for those transactions were determined by PHS pursuant to Sect. 602 of the Veterans Health Care Act of 1992.

Also, in figuring wholesale sales, you need not include the chargebacks required to satisfy end-user purchases by the entities at prices determined by PHS under Sect. 602, or at prices set in negotiations with the PHS Section 602 pharmaceutical prime vendor (PPV) and any subcontractors. However, sales to these entities at prices not negotiated by the Sect. 602 PPV and lower than Sect. 602 statutorily calculated prices must be included in non-FAMP calculations. Finally, sales of specific inpatient covered drugs to disproportionate share hospitals at Sect. 602 prices may be excluded from non-FAMP if you have properly obtained a "hold harmless letter" from VA (see October 19, 2001, Dear Manufacturer Letter).

Any VA-approved changes in non-FAMP methodology (for example, the 90/10 Rule or smoothing of some of the elements in the non-FAMP calculation) require the 3Q non-FAMP Old to be restated using the new methodology to ensure an apples-to-apples comparison for the purposes of the additional discount. Any non-FAMP methodology change that is due to errors, requires a self-disclosure to the VA as instructed in Attachment E.

**VA must require that all wholesale sales (or direct sales where those are the proper beginning point) used for 2022 annual and third quarter 2022 non-FAMP reports (to be filed this November) be reduced by amounts**

reflecting certain TRICARE Retail Network usage data posted or transmitted by DoD during the FY 2022 12-month reporting period, because the TRICARE usage constitutes sales to the Federal Government.

Manufacturers will use DoD's payment-due dates to decide which TRRx usage may be ascribed to the relevant reporting periods (See chart below). Covered drug scripts filled for TRICARE beneficiaries through the TRRx/T-Pharm Network should be treated by manufacturers as sales to the Federal Government, for non-FAMP reporting purpose, beginning on the payment-due date transmitted by DoD to the manufacturer in the File containing the manufacturer's quarterly DoD usage data and refund invoice.

Quarter	Billing Period	Refund Payment Due Date
Q2 2021	April - June 2021	November 22, 2021
Q3 2021	July - September 2021	February 21, 2022
Q4 2021	October - December 2021	May 20, 2022
Q1 2022	January - March 2022	August 22, 2022

After PBM receives a company's non-FAMP data, PBM will calculate the [Change in non-FAMP], [Additional Discount], and [2023 Federal Ceiling Price] for each covered drug item subject to the 2022 annual reporting requirements for 2023 FCPs. PBM will send you an Excel workbook (.xls) via e-mail of your company's calculated 2023 FCPs after the non-FAMP data has been calculated. **If your company does not agree with any of VA's calculations of the FCPs, you must formally notify VA within two workdays after VA sends the email. If you submit any corrected annual non-FAMP reports, they will be accepted on a provisional basis but will be subject to audit by the Office of Inspector General (OIG).**

The quarterly non-FAMP report for the third quarter of 2022 consists of the same data as the "new non-FAMP" (07/01/2022 to 09/30/2022) reported on the 2022 annual calculation form, which is due by **November 15, 2022**. Consequently, it will not be necessary to submit the non-FAMP third quarter 2022 report separately. However, companies that do not meet the November 15, 2022, annual reporting deadline will be subject to penalties for late data reporting as described in the MA, paragraph (IV) (B). **Please note that 38 U.S.C. 8126 (e) (2) and Sect. 1927 (b) (3) of the Social Security Act (reflected in the MA) impose a civil money penalty on late reporting manufacturers in the amount of \$10,000.00 for each day in which required information has not been provided. VA asks that you submit the required annual data as soon as possible after the CPI-U change is posted in October and you receive this e-mail.**

Section 8126 (e) of the Law states that quarterly non-FAMP reports are due 30 days after the end of the quarter. These figures should be as accurate as possible, since they serve as an indicator of pricing trends and will be used during OIG reviews. Nevertheless, to assist companies in providing the most accurate quarterly non-FAMP calculations possible, PBM will not seek imposition of late penalties for unreported data until 45 days after the end of each quarter. **The same 45-day forbearance applies to filing Temporary and Permanent New Drug non-FAMPs.** Again, please note that each year the non-FAMP third quarter data is submitted as part of the Annual Report (which is due 45 days after the end of the third quarter).

If you have any questions about any of the above information, please call Cheryl Kohutynski or Dustin Ehster, at (708) 786-7985 or (708) 786-4387, respectively.

Sincerely,



Jennifer Martin, PharmD  
Deputy Chief Consultant  
Pharmacy Benefits Management Services  
VACO Pharmacy Service

## A. METHODOLOGY CHANGE REQUEST

DUE DATE: 10/29/2022

**Purpose:** Allows the company to request review and approval from VA of a change in their methodology used to calculate non-FAMP data for the 2022 annual reporting year, and to request approval of restated 3Q2021 (non-FAMP OLD) recalculated under the new methodology (for purposes of an apples-to-apples additional discount calculation). The VA Office of Inspector General OIG will review these requests and make recommendation to the VA. This request can also be used to notify VA and PBM of pending and approved requests. At this point, and to reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company.

**NOTE: This format is to request non-FAMP methodology changes in advance of the due date (Oct 29, 2022). Instructions: Requesting Modifications to Existing Methodology Used to Calculate non-FAMP**

1. Prepare a letter requesting approval for a change in calculation methodology.
2. Specify the reasons for the change in methodology and provide all supporting documentation.
3. In the workbook, identify the 3Q2021 values impacted by the methodology change.
4. Send original workbook via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) including option (a),(b) or (c)-(see example e-mail below):
  - a. For **new requests**, keep line number 1 in the body of the e-mail and populate the dispute\_nfamp\_old with “Y” and provide the rev\_nfamp\_old values
  - b. For **pending** requests, keep line number 2 in the body of the e-mail and populate the dispute\_nfamp\_old with “Y” and provide the rev\_nfamp\_old values
  - c. **If VA has already approved your company’s methodology change request but the values in the annual workbook do not reflect the change, please send an e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov); populate the dispute\_nfamp\_old field with “Y” and populate the restated 3Q 2021 values in “rev\_nfamp\_old” fields; include documented OIG review and recommended approval and update the subject line with the FSS contract number and “Methodology Change Approved”**
5. For options 4(a) & (b) above, subject line should include the full FSS contract number + manufacturer’s name, and the words: “METHODOLOGY CHANGE”
6. OIG will review the request and any associated documentation prior submitting its recommendation to the VA, who has the final decision. The 2021 3Q NFAMP Old must be restated with the new methodology to ensure an apples-to apples comparison for the purposes of the additional discount. If OIG recommends accepting the proposed methodology, OIG will [communicate its recommendation to \[AMMHIN.PL102585@va.gov\]\(mailto:AMMHIN.PL102585@va.gov\)](#). The VA will then notify the contractor of its decision.
7. Upon approval, PBM will use the updated methodology (revised 3Q OLD values) to calculate 2023 FCPs

Example:

Send	To...	AMMHIN.PL102585@va.gov
	Cc...	
	Bcc...	
	Subject:	V797P-XXXXX Methodology Change + Manufacturer Name
	Attached:	Company ABC_sample V797D-123456.xls (23 KB)

ATTN: Office of Inspector General

Dear VA,

FSS contract **[insert full FSS contract number]:**

1. is submitting **a new request** for a change in the methodology used to calculate NFAMP data for this year’s Public Law.
2. has **already submitted a request** for a change in methodology to calculate NFAMP data for this year’s Public Law, and would like an updated status.

Attached are the supporting document(s) for the change in methodology including the original Excel workbook received populated with 3Q NFAMP old values impacted by this change.

Sincerely,

Pharmaceutical Vendor

**B. WORKBOOK VERIFICATION DISPUTES**

**RETURN DATE: 10/29/2022**

**Purpose:** For the manufacturer to notify the VA of any disputes concerning the accuracy of the annual workbook contents provided for verification. Disputes can be a September 30 FSS price, **and/or** a 3Q CY 2021 (non-FAMP OLD) dispute (unrelated to methodology change) **and/or** a **potentially omitted covered item(s)**.

**Instructions: How to Submit FSS price disputes and/or 3Q CY 2021 (non-FAMP Old) disputes unrelated to methodology changes and/or a potentially omitted covered item(s). NOTE: Items introduced after 04/01/2022 may not be included in this year’s annual workbook for 2023 FCP calculations (exceptions are covered drug NDC changes of existing item(s) and divested/acquired items).**

1. Upon receipt of your company’s Excel workbook, review the covered items where potential disputes exist. Multiple disputes may exist in the Excel workbook.
2. **To dispute the FSS price and/or 3Q CY 2021 price:** Mark column W (Dispute\_fss) with a “Y” in the Excel workbook; to dispute the 3Q CY 2021, mark column X (Dispute\_nfamp\_old) with a “Y” in the Excel workbook. *See example below.*

U	V	W	X	Y	Z
fss	ssmax	nfamp_old	nfamp	nfamp_new	cnt_no
company_of	vendor	Dispute_fss	Dispute_nfamp_old	rev_fss_price	rev_nfamp_old
5	22.52	22.86	35.75		
					V123P-4567D
5	21.01	221.33	30.01		
					V123P-4567D
5	21.01	21.33	35.75		
					V123P-4567D
5	21.01	21.33	35.75		
					V123P-4567D

*Note that for one of these NDCs, there is more than one type of dispute (FSS dispute and 3Q CY 2018 dispute).*

3. For each column populated with a “Y”, input a revised value in the respective column:
  - a. For disputed FSS prices, input the revised FSS price in column Y (without IFF/FET).
  - b. For disputed 3Q 2021 VALUES, input the revised 3Q 2021 value in column Z.
4. The following apply to inputs made in Column Y (rev\_fss\_price):
  - a. Ensure the FSS price does not include the 0.5% Industrial Funding Fee (IFF)
  - b. Ensure the FSS price does not include the Federal Excise Tax (FET) for vaccines
  - c. Attach copies of modifications or contract award documents to support manufacturer’s FSS price dispute
5. The following apply to inputs made in column Z (rev\_nfamp\_old):
  - a. Provide document(s) to support the disputed 3Q 2021 value(s)
6. Subject heading should include the full contract number and the words “Dispute Notification”

Send

To: AMMHIN.PL102585@va.gov

Cc:

Bcc:

Subject: V797D-123456 + Dispute Notification

Attached: Company ABC sample V797D-123456.xls (23 KB); FSS Mod Form 216.pdf (77 KB); FSS Mod Form 309.pdf (77 KB)

Dear VA,

Company ABC has reviewed their workbook. The following potential disputes have been identified **(list all applicable disputes)**:

- FSS price as of Sept 30
- 3Q 2021 (nfamp\_old) Dispute
- Omitted Item

As instructed in the DML, the original workbook and supporting documents have been submitted for consideration.

**B. WORKBOOK VERIFICATION DISPUTES (cont'd)**

**RETURN DATE: 10/29/2022**

7. **To notify PBM of a potential omission:** Identify potential covered item(s) omitted from workbook.
8. In the body of the e-mail, provide the data for the following fields (see example below):
  - NDC\_11, Date of Market Entry, Trade & Generic Name
  - Proposed 09/30 FSS price (without IFF/FET)
  - 2022 annual non-FAMP value (10/01/2021 to 9/30/2022)
  - 3Q Calendar Year 2021 (non-FAMP OLD) value (07/01/2021 to 09/30/2021), if applicable
  - 3Q Calendar Year 2022 (non-FAMP NEW) value (07/01/2022 to 09/30/2022), if applicable
  - Indicate if omitted item is due to a change of NDC (Yes/No/)
    - If “Y”, please update *Date Market Entry* column with the date of the New NDC

**Dear PBM:**

FSS contract number *insert full or pending contract number here* believes the item(s) listed below should have been included in this year's workbook for the following reason(s):

NDC11	Date of Market Entry	Trade Name	Generic	Annual non-FAMP value	3Qnon-FAMP OLD value	3Qnon-FAMP New value	42-2A NDC Change (Y/N?)	Reason
00011222233	3/18/2021	DRUG BRAND CREAM	GENERIC CREAM					
11111222233	3/28/2021	DRUG BRAND BOTTLE	GENERIC BOTTLE					

9. Subject heading should include the full contract number and the words “Dispute Notification”
10. The original Excel workbook received should be returned via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov).
11. Attach copies of modifications or contract award documents to support manufacturer’s FSS price dispute.
12. PBM, FSS and OIG will work to resolve issues. Similar to the 2021 reporting year and to reduce e-mail traffic, a corrected workbook will not be re-issued. Omitted item(s) will be included in the final FCP report to the company.
13. PBM will only process the data after all disputes have been resolved. All corrected information will be included in the final 2023 FCP calculation workbook.
14. Unresolved item(s) will be tagged for follow-up in the 1Q 2023 CY, on a case-by-case basis.

C.

## COMPLIANCE REMINDERS

**Rounding** - Annual non-FAMP data includes sales from 10/01/2021 to 09/30/2022 (“nfamp” column “R” in Excel workbook) and 3Q non-FAMP NEW data includes sales from 07/01/2022 to 09/30/2022 (“nfamp\_new” column “S” in Excel workbook) and must contain data (i.e., NULL or BLANK is not valid). **Calculation is rounded to two decimal places; rounding up if 3<sup>rd</sup> decimal is  $\geq 5$ .** If there are no reportable sales for the covered item(s), enter “0.00”; negative values should be reported as such.

*Rounding Examples:*                      value of 2.1462 rounds to 2.15  
   value of 2.1449 rounds to 2.14

**Discontinuations** - Covered drug items that are contained in the annual workbook received from PBM but have a pending FSS discontinuation modification should still have a 2022 annual non-FAMP report filed to calculate a 2023 FCP; there is no need for a price-changing FSS Request for Modification (RFM) for 2023, IF the stock of the discontinued drug at wholesalers is exhausted by about Dec. 1, 2022. (In such a case, a proper deletion FSS RFM would be filed before Jan. 1, 2022.) However, if sales of wholesaler stock will continue into 2023, the company must follow all the usual steps to have statutory pricing in place for 2023.

**Flu Vaccines** - The VA has established specific guidelines for reporting the provisional and permanent FCP data for influenza vaccines that are excluded from the workbook. Companies are expected to comply with the reporting requirements of the October 19, 2001, DML for reporting provisional FCP data. For reporting permanent FCP data for influenza vaccines, companies are expected to comply with the reporting requirements outlined in the March 31, 2004, DML.

**Eligibility** - Annual non-FAMP data will not be required to be reported for a new covered drug that was introduced into the commercial market after April 1, 2022 and has not experienced at least one full calendar quarter of sales by September 30, 2022. In addition, the item will not appear in the annual workbook for FCP calculations. (NDC changes are the exception to this rule).

**Permanent FCP establishment** - All new covered drugs that reach Permanent FCP stage after September 30, 2022 (that is, any product with a date of market entry after April 1, 2022) must be reported under separate e-mail from the 2022 annual report. These permanent FCPs will remain in effect for the 2022 calendar year and through the 2023 calendar year until the next annual filing due in November of 2023.

**Dear Manufacturer Letters (DML)** - Library of all DMLs available at the following website:  
<http://www.va.gov/oal/business/fss/publicLaw.asp>.

**NDC Changes** - If a manufacturer of a covered drug changes their NDC, the new NDC number must be added to the contract at the time of launch at the same FCP and contract pricing as the original NDC. Further, both the old and new NDC must remain on contract until the old NDC is off the market and out of the supply chain. The non-FAMP sales data for both the “old” and “new” NDCs must be combined (or blended) when reporting. If new covered drug NDC(s) are not included in the initial workbook received from the Public Law Manager, or if there is a pending FSS NDC Change modification, please follow the directions under omitted items (page 11). The new NDC(s) will be included in the final 2023 FCP workbook.

**Excel workbook** – Several of the cells in PBM’s Excel workbooks are locked and read-only. A copy of an unlocked Excel workbook will be supplied to companies upon request if needed for data processing. However, the final Excel workbook submitted to the Public Law Manager by companies must be the original locked Excel workbook received from PBM.

**TRICARE (TRRx)** - VA has provided further guidance to manufacturers on how to treat sales which become the basis for TRICARE Retail Pharmacy Program (TRRx) rebates (page 8). Additional guidance can be found at: <https://health.mil/About-MHS/Defense-Health-Agency/Operations/Pharmacy-Division/Information-for-Pharmaceutical-Manufacturers/Contact-the-TRICARE-Retail-Refund-Team>.

**FSS Contract Number Changes** - FSS contracts are awarded with a five-year duration period. Your FSS contract may be awarded a new contract number during Public Law season **after** the locked spreadsheet

has been submitted to your company. The newly awarded contract number will be used for the final 2023 FCP workbook.

**D. 2023 FCP DISPUTE PROCESS**

**Instructions: How to Submit a Dispute of the 2023 calculated FCPs for annual reporting year 2022**

**Purpose:** Company is to use this format to dispute or resubmit data for 2023 FCP calculations that are the result of database and/or scrivener errors. If a company wishes to dispute an FCP because it believes the non-FAMP data it provided was in error, it should submit a self-disclosure under Attachment E rather than an FCP Dispute e-mail. If a company wishes to dispute an FCP that was calculated correctly, but it believes is unreasonably low, it should follow the guidance in the February 24, 1993 DML to submit an FCP increase appeal to the VA FCP Nominal Increase Board, via e-mail to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov).

1. In the report, identify all covered items where the 2023 FCP is being disputed due to a data base error.
2. In the body of the e-mail, provide the values for the following fields:
  - NDC\_11 and TRADE\_NAME
  - Calculated FCP and Revised FCP
  - Revised 2022 non-FAMP value (10/01/2021 to 09/30/2022)
  - Revised 3Q Calendar Year 2022 non-FAMP value (07/01/2022 to 09/30/2022)
  - Reason for dispute
3. Include all documentation that would support the dispute or resubmission, as necessary.
4. Subject headings should include the full contract number and title "Dispute FCP Report"

**NOTE: Resubmissions are limited to disputes resulting from database errors only** and reports should be submitted via e-mail to [nonfamp@va.gov](mailto:nonfamp@va.gov).

Example:

Subject: V797X-XXXX DISPUTE Calculated FCPs

---

To whom it may concern:

FSS contract V797-X-XXXX is disputing the 2017 calculated FCP data for the following NDCs:

NDC_11	TRADE_NAME	Calculated FCP	REVISED FCP	REVISED ANNUAL NFAMP	REVISED 3Q NEW NFAMP	REASON FOR DISPUTE
11111222233	DRUG BRAND CREAM	82.79	85.92	75	N/A	Data entry error for ANNUAL NFAMP
00111234501	DRUG BRAND BOTTLE	24.98	18.92	43.91	18.2	data entry errors for ANNUAL/3Q NEW NFAMP

The attached document(s) support the disputed calculated FCPs.

Sincerely,

Pharmaceutical Vendor

**Examples of database errors/reasons in which PBM can immediately address:**

- Revised 3Q 2021 value(s) approved, but not used for the 2023 FCP calculations
  - Revised 3Q 2021 value(s) restated due to an approved change in the non-FAMP calculation methodology
  - Revised Sep 30 FSS price was approved, but not used for the 2023 FCP calculations
  - Omitted item(s) had incorrect 3Q 2021 value applied for the 2023 FCP calculations
- Scrivener's errors during entry (e.g., 3Q values were entered into the annual fields)

**NOTE: Due to the time constraints and review processes involved, 2023 calculated FCPs unrelated to database errors may be delayed.**

**E. SELF-DISCLOSURE**

**Instructions: How to Submit a Self-disclosure for Federal Supply Schedule (FSS) Public Law Non-**

## Compliance or Pricing Errors

**Purpose:** Provides the manufacturer with a process for making a self-disclosure of any Public Law non-compliance or pricing errors that occurred during any period the manufacturer was subject to the Public Law (manufacturing and selling covered drug products). The [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) mailbox will rout self-disclosures to the OIG and the VA Office of General Counsel (OGC) for an audit.

Examples of non-compliance or pricing errors requiring disclosure include (*but are not limited to*):

- Failure to obtain an FSS contract and sign a Master Agreement in a timely manner
- Failure to submit non-FAMP data and add a new covered drug to an FSS contract in a timely manner
- Errors in calculating non-FAMPs
- Misclassifying covered drugs as non-covered drugs
- Deleting covered drugs from an FSS contract prematurely
- Price Reductions Clause Violations that impacted the FCPs
- Incorrect treatment of:
  - NDC number changes
  - New Package Sizes
  - Transferred Drugs

To make a self-disclosure, a manufacturer should do the following:

Prepare a **letter** that states the non-compliance error, what caused the error, what covered drug item(s) (including NDC #s) were affected by the error, specific date ranges when the error(s) occurred, and what remedial action the manufacturer is proposing or has taken.

1. Provide the first commercial sale dates of all NDCs involved, for all self-disclosure issues.
2. Estimated overcharges owed to the Government, if known. If not known, please state this fact in the disclosure letter and explain why an estimated overcharges amount cannot be provided.
3. For transferred drug treatment errors, provide the date that the transferee obtained full legal rights and responsibilities for the products, the transferee's first commercial sale dates, explanation of the treatment of the transferor's remaining inventory, and details of any interim arrangements between the transferor and transferee regarding sales of the products and sales reporting responsibilities to the VA for IFF purposes.
4. For new package size errors, please provide the NDC number used as the closest package size and the pro-rated calculations
5. Provide supporting documentation for the disclosure including the original and restated non-FAMPS and related FCPs and the detailed non-FAMP methodology used in the calculations.
6. Provide the point of contact(s) for OIG to contact if a review is needed.
7. Send the disclosure letter via e-mail notification to [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov).
8. The email Subject should include the full FSS contract number, manufacturer's name, and the words: "Self- Disclosure".

Example:

Subject:	V797P-XXXXX Manufacturer Name - Self-disclosure
Attached:	Provide all supporting documents

Dear OGC/OIG:

FSS contract V797P-XXXXX would like to report that during a self audit we have discovered the following issues over the course of X years.

Describe the issue

Provide all supporting documentation and contact phone numbers.

Sincerely,

Pharmaceutical Vendor

**F. APPEAL TO THE NOMINAL INCREASE BOARD**

**Instructions: How to Submit a request to the Nominal Increase Board for FCP increases**

**Purpose:** Provides the manufacturer with a process for making an appeal to the Nominal Increase Board to increase the FCP if it is determined that selling at that price would cause the manufacturer to lose money in its overall business. The [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) mailbox will route appeal to the OIG who will review the appeal and make its recommendation to the Nominal Increase Board.

**Guidance:** December 30, 1992, February 24, 1993, & July 15, 1993 Dear Manufacturer Letters

**Before submitting an appeal to the Nominal Increase Board, the manufacturer should first consider if a change in non-FAMP methodology (for example, smoothing the 3Q NFAMPs) eliminates the financial problem.**

**To submit an appeal letter to the Nominal Increase Board, all of the following information must be sent to the [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) mailbox:**

1. The formal nominal increase materials that are outlined in the 1993 Dear Manufacturer Letter (DML). This includes:
  - a. The certification signed by the president of the company found on page 3 of the DML.
  - b. Justification for the increase for each NDC item
  - c. Financial problem that allegedly exists with the statutorily calculated FCP
  - d. Explanation of how it would be in the best interests of VA or another Federal agency to pay more for a covered drug product than the statutory formula specifies
2. The total overall volume of commercial sales for all products marketed.
3. The sales percentage of the NDCs that relief is being requested to overall sales of all products marketed.
4. The sales percentage of total Government sales to total sales volume.
5. The Cost of Goods Sold per unit for each NDC in the format shown below:
  - a. Direct Materials
  - b. Direct Labor
  - c. Fixed Overhead (specific overhead costs must be defined and itemized)
  - d. Variable Overhead (specific overhead costs must be defined and itemized)
  - e. Other Costs (each type of other cost must be defined and itemized)

	<u>NDC #</u>	<u>NDC #</u>	<u>NDC #</u>
	<u>Product Name</u>	<u>Product Name</u>	<u>Product Name</u>
<b>2022 FCP Currently in Place</b>			
<b>Less: Cost of Goods Sold - Per Unit</b>			
Direct Materials			
Direct Labor			
Fixed Overhead			
Variable Overhead			
<b>Total Cost of Goods Sold</b>	\$0.00	\$0.00	\$0.00
<b>Other Costs -- Please Detail and Define</b>			
<b>Total Other Costs</b>	\$0.00	\$0.00	\$0.00
<b>Net Profit/Loss Per Unit</b>	\$0.00	\$0.00	\$0.00

6. Provide the point of contact(s) for OIG for follow-up questions.
7. Email the appeal letter to the [AMMHIN.PL102585@va.gov](mailto:AMMHIN.PL102585@va.gov) mailbox
8. The email Subject should include the full FSS contract number, manufacturer’s name, and the words: “Appeal to the Nominal Increase Board”.
9. Deadline for submissions each year is September 1<sup>st</sup>.